Harbor Capital Advisors Inc. Acquires 16,466 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Harbor Capital Advisors Inc. increased its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 12.8% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 145,379 shares of the medical equipment provider’s stock after buying an additional 16,466 shares during the period. Harbor Capital Advisors Inc. owned about 0.21% of Lantheus worth $13,006,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Wilmington Savings Fund Society FSB bought a new position in shares of Lantheus during the 3rd quarter worth $25,000. Signaturefd LLC increased its stake in shares of Lantheus by 40.5% in the third quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider’s stock worth $35,000 after purchasing an additional 92 shares in the last quarter. Nkcfo LLC bought a new stake in shares of Lantheus in the second quarter valued at approximately $47,000. UMB Bank n.a. lifted its stake in shares of Lantheus by 42.1% during the 3rd quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider’s stock valued at $47,000 after buying an additional 126 shares in the last quarter. Finally, Kathleen S. Wright Associates Inc. purchased a new position in Lantheus in the 3rd quarter valued at approximately $51,000. 99.06% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the company. Truist Financial restated a “buy” rating and set a $120.00 target price (down previously from $135.00) on shares of Lantheus in a research report on Friday, November 8th. The Goldman Sachs Group began coverage on Lantheus in a research note on Wednesday, December 18th. They issued a “buy” rating and a $143.00 target price for the company. StockNews.com cut Lantheus from a “buy” rating to a “hold” rating in a research report on Thursday, November 21st. Finally, JMP Securities decreased their price target on shares of Lantheus from $125.00 to $112.00 and set a “market outperform” rating on the stock in a report on Thursday, November 7th. One analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $131.86.

Lantheus Trading Up 2.4 %

Shares of LNTH stock traded up $2.21 during trading hours on Friday, hitting $96.21. 205,932 shares of the company’s stock were exchanged, compared to its average volume of 760,219. The company has a market capitalization of $6.69 billion, a PE ratio of 16.01 and a beta of 0.46. The business’s 50 day simple moving average is $90.63 and its 200-day simple moving average is $99.30. Lantheus Holdings, Inc. has a 12-month low of $50.20 and a 12-month high of $126.89.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.